EffRx Receives U.S. Orphan Drug Designation For EX404 For Treatment Of Pediatric Polycystic Ovary Syndrome
6/10/2014 9:59:04 AM
ZURICH--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by